Clinical Trials

Zenocutuzumab
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy trial)

Zeno (zenocutuzumab, or MCLA-128) is an investigational therapeutic candidate being studied in the eNRGy trial, a phase 1/2 clinical study in cancer patients who have solid tumors that have a specific genetic abnormality called an NRG1 fusion. Zeno is believed to work by blocking the protein produced by the NRG1 fusion that has cancer-driving activity.

At this time, there is no approved therapy for the specific treatment of NRG1 fusion-positive (NRG1+) solid tumors.

The eNRGy trial is enrolling patients with NRG1+ cancers at more than 60 medical centers around the world. The eNRGy trial is assessing the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancers, in patients across three cohort groups: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors.

Further details about the eNRGy clinical trial for Zeno, including current trial sites, can be found at Merus’ trial website at http://www.nrg1.com or by calling 1-833-NRG-1234.

Information is also available at the clinicaltrials.gov website.

Early Access Program
Patients with NRG1+ solid tumors that are otherwise unable to participate in an applicable clinical trial may be eligible to participate in the Early Access Program for Zeno (MCLA-128). Further details about the Zeno Early Access Program can be found at Merus’ trial website www.nrg1.com or by calling 1-833-NRG-1234. Details on Merus’ Early Access Policy are available here. Information is also available at the clinicaltrials.gov website: Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
MCLA-158
(Petosemtamab)
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Peto (petosemtamab, or MCLA-158) is being developed for the potential treatment of solid tumors. Our phase 1 clinical trial of Peto is ongoing in the dose expansion phase of the open-label, multicenter trial. Enrollment of patients in dose expansion cohorts continues and early evidence of clinical activity in advanced Head & Neck Squamous Cell Carcinoma has been observed.

More information is available at the clinicaltrials.gov website.

MCLA-145
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

MCLA-145 is currently being evaluated in a phase 1 open-label, multicenter, dose escalation study, including a safety dose expansion phase, in patients with solid tumors followed by a planned dose expansion phase.

More information is available at the clinicaltrials.gov website.

MCLA-129
A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

MCLA-129 is currently being evaluated in a phase 1/2 open-label, multicenter, dose escalation study, followed by a dose expansion phase, in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors followed by a planned dose expansion phase.

More information is available at the clinicaltrials.gov website.

 

Unless otherwise noted, we are providing this information as of May 9, 2022, and expressly disclaim any duty to update any of the provided information. Merus’ product candidates pipeline will change over time as molecules move through the drug development process, including potentially progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Merus’ most recent Quarterly Report on Form 10-Q and in Merus’ other periodic reports on Form 10-K, Form 10-Q and Form 8-k filed with the SEC, and actual results may vary materially. Merus provides this information as of the date above and does not undertake any obligation to update any forward-looking statements contained on these tables as a result of new information, future events or otherwise.

All Company therapeutic candidates described or mentioned herein are investigational and have not yet been approved for marketing by any regulatory authority.